Tumor markers in evaluating the response to radiotherapy in unresectable pancreatic cancer

Hepato-Gastroenterology

Volumn 45, Issue 21, 1998, Pages 867-872

  Okusaka, Takuji ^a   Okada, Shuichi ^a   Sato, Tosiya ^b   Wakasugi, Hideyuki ^c   Saisho, Hiromitsu ^d   Furuse, Jyunji ^e   Ishikawa, Osamu ^f   Matsuno, Seiki ^g   Yokoyama, Shinji ^h  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b INSTITUTE OF STATISTICAL MATHEMATICS   (Japan)

^c NATIONAL KYUSHU CANCER CENTER   (Japan)

^d CHIBA UNIVERSITY   (Japan)

^e NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^f CENTER FOR ADULT DISEASES   (Japan)

^g TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

Author keywords

CA 19 9; CEA; Pancreatic cancer; Radiotherapy; Survival

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD LEVEL; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PANCREAS CANCER; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 0031874821     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Hayakawa T, Kondo T, Shibata T, Hamano H, Kitagawa M, Sakai Y, Ono H. Sensitive serum markers for detecting pancreatic cancer. Cancer 1988; 61:1827-1831.
2. Ona FV, Zamcheck N, Dhar P, Moore T, Kupchik HZ. Carcinoembryonic antigen (CEA) in the diagnosis of pancreatic cancer. Cancer 1973; 31:324-327.
3. Del Favero G, Fabris C, Plebani M, Panucci A, Piccoli A, Perobelli L, Pedrazzoli S, Baccaglini U, Burlina A, Naccarato R. CA 19-9 and Carcinoembryonic antigen in pancreatic cancer diagnosis. Cancer 1986; 57: 1576-1579.
4. Safi F, Roscher R, Beger HG. Tumor markers in pancreatic cancer. Sensitivity and specificity of CA19-9. Hepato-Gastroenterol 1989; 36: 419-423.
5. van den Bosch RP, van Eijck CH, Mulder PG, Jeekel J. Serum CA19-9 determination in the management of pancreatic cancer. Hepato-Gastroenterol 1996; 43: 710-713.
6. Yasue M, Sakamoto J, Teramukai S, Morimoto T, Yasui K, Kuno N., Kurimoto K, Ohashi Y. Prognostic values of preoperative and postoperative CEA and CA19.9 levels in pancreatic cancer. Pancreas 1994; 9: 735-740.
7. Lundin J, Roberts PJ, Kuusela P, Haglund C. The prognostic value of preoperative serum levels of CA 19-9 and CEA in patients with pancreatic cancer. Br J Cancer 1994; 69: 515-519.
8. Ishii H, Okada S, Sato T, Wakasugi H, Saisho H, Furuse J, Ishikawa O, Matsuno S, Yokoyama S. CA19-9 in evaluating the response to chemotherapy in advanced pancreatic cancer. Hepato-Gastroenterol 1997; 44: 279-283.
9. Wong A, Chan A. The use of the tumor marker CA19-9 in evaluating the response to tamoxifen therapy in patients with unresectable adenocarcinoma of the pancreas. Eur J Cancer 1995; 31A: 2118-2119.
10. Willett CG, Daly WJ, Warshaw AL. CA 19-9 is an index of response to neoadjunctive chemoradiation therapy in pancreatic cancer. Am J Surg 1996; 172: 350-352.
11. Del Favero G, Fabris C, Panucci A, Basso D, Plebani M, Baccaglini U, Leandro G, Burlina A, Naccarato R. Carbohydrate antigen 19-9 (CA 19-9) and carcinoembryonic antigen (CEA) in pancreatic cancer. Role of age and liver dysfunction. Bulletin Cancer. 1986; 73: 251-255.
12. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. Who Offset publication no. 48. Geneva: World Health Organization, 1979.
13. Cox DR. Regression models and life-tables [with discussion]. J R Stat Soc 1972; 34 [Series B]: 187-220.
14. Statistics and Information Department, Minister's Secretariat, Ministry of Health and Welfare. Vital Statistics of Japan 1995. Tokyo: Ministry of Health and Welfare. 1997 (in Japanese).
15. Aoki K, Okada S, Moriyama N, Ishii H, Nose H, Yoshimori M, Kosuge T, Ozaki H, Wakao F, Takayasu K, Mukai K. Accuracy of computed tomography in determining pancreatic cancer tumor size. Jap J Clin Oncol 1994; 24:85-87.
16. Okusaka T, Okada S, Ishii H, Nose H, Nakasuka H, Nakayama H, Nagahama H. Clinical response to systemic combined chemotherapy with 5-fluorouracil and cisplatin (FP therapy) in patients with advanced pancreatic cancer. Jap J Clin Oncol 1996; 26:215-220.